| There is currently great interest in drug repurposing of anti-interleukin-6 (IL-6) agents for the treatment of COVID-19 patients, mostly in the advanced disease stage. |
| Despite the promising effects of anti-IL-6 agents, available clinical evidence is limited and only partly present for tocilizumab. |
| While waiting for more robust clinical data to support the efficacy of anti-IL-6 agents in COVID-19 patients, their potential toxicity should be carefully monitored and managed whenever clinicians decide to treat patients with these agents. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.